Bluejay Therapeutics has two product lines focused on the detection and care of hepatitis B. The funding from this round will go to support the clinical development of these drugs, according to the Aug. 16 Bluejay Therapeutics news release.
The series B funding round was led by Arkin Bio Ventures. Alon Lazarus, PhD, an investment manager at Arkin Bio Ventures, will join the Bluejay Therapeutics board of directors.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.